Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214 · clinicaltrials.gov ↗
ACTIVE_NOT_RECRUITING
Status
212
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Fondazione Italiana Linfomi - ETS